Organ-specific uptake of extracellular vesicles secreted by urological cancer cells

Linxweiler, Johannes; Kolbinger, Anja; Saar, Matthias; Stöckle, Michael; Junker, Kerstin

doi:10.1016/s0302-2838(21)00916-7

Cited by 1 publication

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EVs from UC cell lines have been demonstrated to influence tumour‐associated signalling, via, for example, metabolic or immune regulation, and EVs isolated from plasma or urine of UC patients constitute a potential source of BMs [19,24–39]. Although mass spectrometry (MS) followed by bioinformatics is a common approach for EV proteome analyses, such methodology may not always be feasible as the amount of EVs that can be isolated from plasma varies due to dynamic processes.…”

Section: Introductionmentioning

confidence: 99%

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome

et al. 2022

View full text Add to dashboard Cite

The prognosis of metastatic urothelial carcinoma (mUC) patients is poor, and early prediction of systemic therapy response would be valuable to improve outcome. In this exploratory study, we investigated protein profiles in sequential plasma‐isolated extracellular vesicles (EVs) from a subset of mUC patients treated within a Phase I trial with vinflunine combined with sorafenib. The isolated EVs were of exosome size and expressed exosome markers CD9, TSG101 and SYND‐1. We found, no association between EVs/ml plasma at baseline and progression‐free survival (PFS). Protein profiling of EVs, using an antibody‐based 92‐plex Proximity Extension Assay on the Oncology II ® platform, revealed a heterogeneous protein expression pattern. Qlucore bioinformatic analyses put forward a protein signature comprising of SYND‐1, TNFSF13, FGF‐BP1, TFPI‐2, GZMH, ABL1 and ERBB3 to be putatively associated with PFS. Similarly, a protein signature from EVs that related to best treatment response was found, which included FR‐alpha, TLR 3, TRAIL and FASLG. Several of the markers in the PFS or best treatment response signatures were also identified by a machine learning classification algorithm. In conclusion, protein profiling of EVs isolated from plasma of mUC patients shows a potential to identify protein signatures that may associate with PFS and/or treatment response.

show abstract

Section: Introductionmentioning

confidence: 99%

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome

et al. 2022

View full text Add to dashboard Cite

show abstract

Organ-specific uptake of extracellular vesicles secreted by urological cancer cells

Abstract: This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).

Cited by 1 publication

References 24 publications

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome

Profiling of extracellular vesicles of metastatic urothelial cancer patients to discover protein signatures related to treatment outcome

Contact Info

Product

Resources

About